Proton-pump inhibitor use in combination with a CDK4/6 inhibitor: is formulation the issue?
The Oncologist · 06.08.2026 · 31 (9)
DOI: 10.1093/oncolo/oyag293 ↗Kurz gefasst
Editorial in der Zeitschrift The Oncologist, online erschienen am 31.07.2026. Verfasst von Calum Polwart. Beteiligte Einrichtung: South Tees Hospitals NHS Foundation Trust, James Cook Cancer Institute, Middlesborough TS4 3BW, United Kingdom. Die Arbeit nennt 4 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- South Tees Hospitals NHS Foundation Trust, James Cook Cancer Institute, Middlesborough TS4 3BW, United Kingdom.
ORCID-Profile: Calum Polwart
Zitieren
APA
Polwart, C. (2026). Proton-pump inhibitor use in combination with a CDK4/6 inhibitor: is formulation the issue?. The Oncologist, 31(9). https://doi.org/10.1093/oncolo/oyag293
Vancouver
Polwart C. Proton-pump inhibitor use in combination with a CDK4/6 inhibitor: is formulation the issue?. The Oncologist. 2026;31(9). doi:10.1093/oncolo/oyag293
BibTeX
@article{Polwart2026,
author = {Polwart, Calum},
title = {Proton-pump inhibitor use in combination with a CDK4/6 inhibitor: is formulation the issue?},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {9},
doi = {10.1093/oncolo/oyag293}
}
EUVIMED